* any other concomitant diseases or conditions, which, in the opinion of the research doctor, may distort research results, restrict the rights of a volunteer or put him/her at greater risk. * contraindications to the use of the investigated medicinal product. * individual intolerance to the ingredients included in the composition of the investigational medicinal product. * pregnancy or breastfeeding. * doubtful result of a pcr test for the presence of rna sars-cov-2 in the biomaterial obtained by nasopharyngeal smear. * participation in a clinical trial using study therapy within 30 days prior to enrollment in this study. * disagreement to follow in the research reliable contraceptive measures (abstinence; or a combination of 2 different methods: for example, barrier and spermicides, or barrier and intrauterine device, or barrier and hormonal, etc.) - for participants with saved reproductive potential.

* any other concomitant diseases or conditions, which, in the opinion of the research doctor, may distort research results, restrict the rights of a volunteer or put him/her at greater risk. * contraindications to the use of the investigated medicinal product. * individual intolerance to the ingredients included in the composition of the investigational medicinal product. * pregnancy or breastfeeding. * doubtful result of a pcr test for the presence of rna sars-cov-2 in the biomaterial obtained by nasopharyngeal smear. * participation in a clinical trial using study therapy within 30 days prior to enrollment in this study. * disagreement to follow in the research reliable contraceptive measures (abstinence; or a combination of 2 different methods: for example, barrier and spermicides, or barrier and intrauterine device, or barrier and hormonal, etc.) - for participants with saved reproductive potential.

- any other concomitant diseases or conditions, which, in the opinion of the research doctor, may distort research results, restrict the rights of a volunteer or put him/her at greater risk. - contraindications to the use of the investigated medicinal product. - individual intolerance to the ingredients included in the composition of the investigational medicinal product. - pregnancy or breastfeeding. - doubtful result of a pcr test for the presence of rna sars-cov-2 in the biomaterial obtained by nasopharyngeal smear. - participation in a clinical trial using study therapy within 30 days prior to enrollment in this study. - disagreement to follow in the research reliable contraceptive measures (abstinence; or a combination of 2 different methods: for example, barrier and spermicides, or barrier and intrauterine device, or barrier and hormonal, etc.) - for participants with saved reproductive potential.

- any other concomitant diseases or conditions, which, in the opinion of the research doctor, may distort research results, restrict the rights of a volunteer or put him/her at greater risk. - contraindications to the use of the investigated medicinal product. - individual intolerance to the ingredients included in the composition of the investigational medicinal product. - pregnancy or breastfeeding. - doubtful result of a pcr test for the presence of rna sars-cov-2 in the biomaterial obtained by nasopharyngeal smear. - participation in a clinical trial using study therapy within 30 days prior to enrollment in this study. - disagreement to follow in the research reliable contraceptive measures (abstinence; or a combination of 2 different methods: for example, barrier and spermicides, or barrier and intrauterine device, or barrier and hormonal, etc.) - for participants with saved reproductive potential.